Megadeals are largely missing in an otherwise healthy M&A environment for biopharma.
Biopharma’s deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries.
But there’s one …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
As biologics dominate biopharma pipelines, manufacturing hurdles trip up new launches: report
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
BeOne wins FDA approval in lymphoma race
A political contest in the U.K. could shake up drug pricing
Astellas treatment offers new hope to a devastated rare disease community
A year after Vertex’s big launch, pain drug research faces a pivotal moment
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the…
Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of…
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune…
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson.
Executives seek “skin in the game” despite signs of a stock market cooldown.
